Rani Therapeutics appoints Sara Kenkare-Mitra as advisor

Rani Therapeutics Holdings, Inc., a clinical-stage biotechnology company, has appointed Dr. Sara Kenkare-Mitra, a seasoned pharmaceutical executive, as a strategic advisor to its board. The announcement was made by the San Jose, California-based firm on March 25, 2025, as part of its ongoing strategy to strengthen its leadership and accelerate the development of its innovative oral biologic drug delivery platform, the RaniPill. This move aims to leverage Dr. Kenkare-Mitra's extensive experience in drug development and regulatory affairs to advance the company's pipeline through critical clinical and commercial stages. Dr. Kenkare-Mitra brings over three decades of industry expertise, most notably from her previous role as Senior Vice President of Development Sciences at Genentech, a member of the Roche Group. Her career is distinguished by significant contributions to the development and global regulatory approval of numerous major therapeutics. At Rani Therapeutics, her advisory role will be focused on guiding the clinical development strategy for the RaniPill technology, which is designed to enable the oral delivery of drugs that currently require injection, such as certain biologics for chronic diseases. The appointment underscores Rani Therapeutics' commitment to advancing its flagship technology towards commercialization. The RaniPill capsule represents a potential paradigm shift in patient care, aiming to improve adherence and quality of life for individuals requiring frequent injections. With Dr. Kenkare-Mitra's counsel, the company is better positioned to navigate the complex regulatory pathways and strategic partnerships necessary to bring this novel delivery system to market, targeting multi-billion dollar therapeutic areas like rheumatoid arthritis, diabetes, and osteoporosis. This strategic hire occurs as the biotechnology sector increasingly focuses on patient-centric drug delivery solutions. Rani Therapeutics, which became a public company via a SPAC merger in 2021, is advancing several programs through clinical trials. The addition of an advisor of Dr. Kenkare-Mitra's caliber signals a mature phase in the company's growth, aligning expert governance with its mission to transform treatment paradigms for millions of patients worldwide.